Eagle Pharmaceuticals (EGRX) Receiving Somewhat Favorable Press Coverage, Study Finds

News headlines about Eagle Pharmaceuticals (NASDAQ:EGRX) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Eagle Pharmaceuticals earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 44.9579376050329 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of Eagle Pharmaceuticals (NASDAQ EGRX) opened at $53.42 on Tuesday. The company has a current ratio of 5.30, a quick ratio of 5.15 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $797.11, a PE ratio of 8.62 and a beta of 1.24. Eagle Pharmaceuticals has a twelve month low of $45.05 and a twelve month high of $97.15.

A number of brokerages recently commented on EGRX. ValuEngine cut Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday. BidaskClub raised Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, December 2nd. Mizuho decreased their target price on Eagle Pharmaceuticals from $40.00 to $37.00 and set an “underperform” rating on the stock in a report on Wednesday, September 6th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $75.00 target price on shares of Eagle Pharmaceuticals in a report on Friday, October 27th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $75.00 target price (down from $81.00) on shares of Eagle Pharmaceuticals in a report on Thursday, November 9th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $62.33.

TRADEMARK VIOLATION WARNING: “Eagle Pharmaceuticals (EGRX) Receiving Somewhat Favorable Press Coverage, Study Finds” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2018/01/02/eagle-pharmaceuticals-egrx-receiving-somewhat-favorable-press-coverage-study-finds.html.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Insider Buying and Selling by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply